LAMY engages in developing a business tapping the eLearning market and the gaming market by teaching financial knowledge and resource management to children. The company is headquartered in St. Petersburg, Florida. The company went IPO on 2024-04-30. The firm is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
根據最新的財務報表(Form-10K),Un Monde International Ltd 的總資產為 $0,淨損失為 $0
LMMY 的關鍵財務比率是什麼?
Un Monde International Ltd 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
LAMY 的收入按細分市場或地理位置如何劃分?
Un Monde International Ltd 最大收入來源為 Banking and Related Activities,在最近的收益報告中收入為 85,199,000。就地區而言,United States 是 Un Monde International Ltd 的主要市場,收入為 85,199,000。